Treatment by Furosemide
Conditions
Brief summary
Recent in-vitro and in-vivo studies performed by one of the investigators (ESO, ICMPE, UPEC, France) have recently allowed to synthetize a new and easy-to-synthesized chemical compound of the furosemide (pyridinium furosemide) during furosemide degradation by electro-Fenton or bioconversion. The biological properties of pyridinium furosemide are currently under investigation. Furosemide is a diuretics currently used in the treatment of patients with heart failure. The goal of the investigators is to assay pyridinium furosemide in urine of patients treated by furosemide to demonstrate that pyridinium is or not a metabolite of furosemide in humans. This study will contribute to assess the fate of pharmaceutical residues of furosemide in the environment.
Interventions
OTHERNot intervention
None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
Sponsors
Henri Mondor University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Written informed consent 3. Affiliation to social security 4. Known heart failure 5. Treatment by furosemide
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assay of furosemide and pyridinium furosemide in urine of heart failure patients treated by furosemide | 1 day | Assay of furosemide and pyridinium furosemide in urine of heart failure patients treated by furosemide |
Outcome results
None listed